![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Griffin Grp. | LSE:GFF | London | Ordinary Share | GB0009530188 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.625 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1573A Griffin Group PLC 25 June 2004 FOR IMMEDIATE RELEASE 25 June 2004 GRIFFIN GROUP PLC (Griffin Group" or the "Company") Further update on trading and investments As announced at the time of the interim results for the six months ended 31 March 2004, the Company intended to establish over time a small number of AIM traded companies as cash shells. On 14 May 2004, the shares of Orientrose 2 plc ("OR2"), a cash shell in which Griffin has a 60 per cent. shareholding, were admitted to AIM. OR2's strategy is to find a suitable company or business or investment to acquire. OR2's investment criteria is that the target should be profitable or have significant asset value and should operate in a sector that has opportunities for consolidation or further development. Following admission, Griffin has introduced a number of potential investment opportunities to OR2 that are being actively considered by OR2. On 20 May 2004, the shares of Metrocapital plc ("Metrocapital"), a cash shell in which Griffin had a 30.44 per cent. shareholding, were also admitted to AIM. Operational control of Metrocapital on admission to AIM was assumed by the new board and its majority shareholders. On 22 June 2004 Griffin disposed of its entire shareholding in Metrocapital for #211,083 net of expenses, realizing a profit before taxation of #136,083 on sale. Investment banking activity in the US continues to develop satisfactorily. The US based operations of Griffin have recently completed a private placement of $8.5 million for Integrated BioPharma Inc., a leading biopharmaceutical company listed on the American Stock Exchange and participated in a $74.6 million raise for Cypress Bioscience Inc., a biotechnology company listed on NASDAQ, led by Deutsche Bank Securities Inc., CIBC World Markets Corp., Lazard Freres & Co. LLC, Jefferies & Company, and others. ENDS This information is provided by RNS The company news service from the London Stock Exchange END TSTILFLFRDIEFIS
1 Year Griffin Chart |
1 Month Griffin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions